Cannabis in Pediatric Epilepsy

Not medical advice

This article is not medical advice. Pediatric epilepsy is a serious condition. Decisions about anti-seizure medication — including cannabis-derived products — must be made with a pediatric neurologist or epileptologist. Stopping or switching seizure medication without supervision can be life-threatening. Drug interactions between CBD and common anti-epileptic drugs (especially clobazam and valproate) are clinically significant and require monitoring.

Plain-language summary

Some children have epilepsy that does not respond to standard medications. For a small number of rare, severe syndromes — Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex — a purified pharmaceutical form of cannabidiol (CBD), sold as Epidiolex in the US and Epidyolex in Europe, has been shown in randomized controlled trials to reduce seizure frequency. It is FDA-approved for these uses ^[1][2][3].

This is not the same thing as buying a CBD oil at a dispensary or online store. Artisanal and over-the-counter CBD products vary wildly in actual CBD content, often contain THC, and have not been tested in controlled trials in children ^[4]. The story that 'CBD cures childhood epilepsy' is a half-truth: a specific, standardized, prescription CBD reduces seizures in specific syndromes, by a meaningful but not magical amount.

What probably works (strong evidence)

Purified pharmaceutical CBD (Epidiolex/Epidyolex) for three specific syndromes:

• Dravet syndrome. In a randomized, double-blind, placebo-controlled trial, CBD 20 mg/kg/day reduced convulsive seizures by a median 39% vs 13% on placebo ^[1] Strong evidence.
• Lennox-Gastaut syndrome (LGS). Two RCTs showed CBD reduced drop seizures by roughly 40–44% vs ~17–22% on placebo at doses of 10–20 mg/kg/day ^[2][5] Strong evidence.
• Tuberous sclerosis complex (TSC). A 2021 RCT showed CBD 25 mg/kg/day reduced TSC-associated seizures by 48% vs 27% on placebo ^[3] Strong evidence.

These are real, replicated, peer-reviewed results that led to regulatory approval. They are not 'seizure-free' results for most children — they are reductions in frequency, and a minority of patients become seizure-free.

What might work (weak or emerging evidence)

• Other refractory childhood epilepsies. Open-label expanded-access programs reported seizure reductions in mixed pediatric epilepsy populations, but these are uncontrolled and prone to placebo effect and reporting bias ^[6] Weak / limited.
• CBD as add-on for epilepsy in children without one of the approved syndromes. Some neurologists prescribe Epidiolex off-label; results are inconsistent and not supported by RCTs Weak / limited.
• THC:CBD combinations. Limited observational data exist; no good controlled trials in children. Some case series suggest benefit in specific cases, but safety in developing brains is a serious concern Weak / limited.

What doesn't work or has no good evidence

• Artisanal 'CBD-rich' oils as a substitute for prescription CBD. Independent analyses repeatedly find that retail CBD products are mislabeled, with actual CBD content often differing substantially from the label and detectable THC contamination ^[4][7] [evidence:strong that mislabeling is common; evidence:none that these products replicate Epidiolex results].
• 'Charlotte's Web' or any specific cultivar as uniquely effective. The famous case that launched public interest in pediatric CBD is a single child's story. It is not evidence of efficacy Anecdote.
• Cannabis for typical, drug-responsive childhood epilepsy. No evidence supports cannabis over standard anti-epileptic drugs as first-line treatment No data.
• Smoked or vaped cannabis in children. No controlled evidence; pediatric inhalation exposure is not appropriate No data.

What we don't know

• Long-term cognitive and developmental effects of years of CBD exposure in children. Trials have mostly been months, not decades.
• Whether 'whole plant' extracts truly outperform purified CBD (the so-called entourage effect). Claims exist Disputed; rigorous head-to-head trials in children do not.
• Optimal dosing below 10 mg/kg/day — most evidence is at 10–25 mg/kg/day.
• Whether CBD modifies the underlying disease course or only suppresses seizures.
• Effects in epilepsies outside the three approved syndromes at a trial-quality level.

Comparison with standard treatments

Standard anti-epileptic drugs (AEDs) — valproate, levetiracetam, clobazam, lamotrigine, stiripentol, rufinamide, and others — remain first-line for childhood epilepsy. CBD is added on top of existing AEDs, not instead of them, in the trials that led to approval ^[1][2][3].

For Dravet syndrome specifically, stiripentol combined with clobazam and valproate has its own RCT evidence base and is often tried before or alongside CBD ^[8]. For LGS, rufinamide and clobazam have established roles. Ketogenic diet is another evidence-supported option for refractory pediatric epilepsy and is sometimes more effective than any single drug.

CBD's appeal is not that it is dramatically better than these — it isn't — but that it offers an additional option for children who have failed multiple AEDs.

Risks and side effects

Pharmaceutical CBD is not risk-free:

• Elevated liver enzymes (transaminases). Common, especially with concomitant valproate. Requires baseline and follow-up liver monitoring ^[1][2] Strong evidence.
• Sedation and somnolence. Particularly when combined with clobazam — CBD inhibits CYP2C19, raising levels of the active clobazam metabolite N-desmethylclobazam ^[9] Strong evidence. Clobazam dose reduction is often needed.
• Decreased appetite, diarrhea, fatigue, vomiting — reported in trials at meaningfully higher rates than placebo ^[1][2].
• Drug interactions. CBD interacts with several AEDs and other medications via CYP450 pathways ^[9].
• Artisanal product risks. Unknown THC content, contaminants (pesticides, heavy metals, solvents), and inaccurate labeling can produce unexpected effects, including psychoactivity in a child ^[4][7].

Practical bottom line

If a child has Dravet syndrome, Lennox-Gastaut syndrome, or tuberous sclerosis complex and has not responded adequately to standard treatment, pharmaceutical CBD is a legitimate, evidence-based option to discuss with a pediatric epileptologist. For other situations, the evidence is far thinner than the marketing suggests. Buying a bottle of CBD oil online to treat a child's seizures is not equivalent to a prescription of Epidiolex, and may delay effective care.

See also: Cannabidiol (CBD), Drug interactions with cannabis, The entourage effect.

Sources

How this page was made